Edesa Biotech, Inc. Common Shares (EDSA) Stock Price

EDSAStock

$4.45+83.33%52W

Market Cap$42.90M

P/E—

PEG Ratio—

Div yield—

Beta1.17

EDSA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)333.20%

Price vs S&P 500 (4W)-14.52%

VGM Score37.04

Book Value / Share (Quarterly)$1.15

P/TBV (Annual)1.66x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.85

Price vs S&P 500 (YTD)197.90%

Gross Margin (TTM)94.65%

Net Profit Margin (TTM)-1935.58%

EPS (TTM)$-1.34

10-Day Avg Trading Volume0.11M

EPS Excl Extra (TTM)$-1.34

EPS (Annual)$-1.93

ROI (Annual)-311.46%

Gross Margin (Annual)94.65%

Net Profit Margin (5Y Avg)-1517.63%

Cash / Share (Quarterly)$1.13

ROA (Last FY)-161.78%

EBITD / Share (TTM)$-1.43

ROE (5Y Avg)-157.84%

Operating Margin (TTM)-1946.75%

Cash Flow / Share (Annual)$-1.03

P/B Ratio5.09x

P/B Ratio (Quarterly)4.56x

Net Income / Employee (Annual)$-362,900

EV / Revenue (TTM)127.49x

Net Interest Coverage (TTM)-7021.32x

ROA (TTM)-75.37%

EV / EBITDA (TTM)16.48x

EPS Incl Extra (Annual)$-1.93

Current Ratio (Annual)10.67x

Quick Ratio (Quarterly)4.67x

3-Month Avg Trading Volume0.37M

52-Week Price Return83.33%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.93

P/S Ratio (Annual)157.92x

Asset Turnover (Annual)0.03x

52-Week High$20.32

Operating Margin (5Y Avg)-1541.38%

EPS Excl Extra (Annual)$-1.93

Tangible BV CAGR (5Y)6.34%

26-Week Price Return344.44%

Quick Ratio (Annual)10.60x

13-Week Price Return-59.52%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.76x

Enterprise Value$41.92M

Asset Turnover (TTM)0.04x

Book Value / Share Growth (5Y)-23.44%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)3.05x

Pretax Margin (Annual)-1935.34%

Cash / Share (Annual)$1.51

3-Month Return Std Dev102.55%

Gross Margin (5Y Avg)-12.60%

Net Income / Employee (TTM)$-614,300

ROE (Last FY)-311.46%

Net Interest Coverage (Annual)-168.89x

EPS Basic Excl Extra (Annual)$-1.93

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.34

Receivables Turnover (Annual)0.00x

ROI (TTM)-82.34%

P/S Ratio (TTM)157.92x

Pretax Margin (5Y Avg)-1517.32%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.47

Price vs S&P 500 (52W)65.02%

Year-to-Date Return209.86%

5-Day Price Return-22.94%

EPS Normalized (Annual)$-1.93

ROA (5Y Avg)-111.64%

Net Profit Margin (Annual)-1935.58%

Month-to-Date Return-13.89%

Cash Flow / Share (TTM)$-3.45

EBITD / Share (Annual)$-2.14

Operating Margin (Annual)-1946.72%

ROI (5Y Avg)-157.84%

EPS Basic Excl Extra (TTM)$-1.34

P/TBV (Quarterly)5.62x

P/B Ratio (Annual)1.40x

Inventory Turnover (TTM)1.83x

Pretax Margin (TTM)-1935.34%

Book Value / Share (Annual)$1.74

Price vs S&P 500 (13W)-62.32%

Beta1.17x

Revenue / Share (TTM)$0.00

ROE (TTM)-82.34%

52-Week Low$0.72

vGradeD

mGradeC

vgmGradeD

EDSA Earnings Surprise History

Q2 25-0.25est. -0.26

Q3 25-0.32est. -0.27

Q4 25-0.28est. -0.45

Q1 26-0.49est. -0.26

Q2 26-0.60est. -0.43

EDSA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

4.11

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
EDSAEdesa Biotech, Inc. Common Shares	D	—	C	$4.45
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Edesa Biotech, Inc. Common Shares

Edesa Biotech is a biotechnology company developing therapies for inflammatory and immune-related diseases. Its lead candidate, EB06, is a monoclonal antibody targeting CXCL10 being developed for vitiligo as a potential steroid-sparing treatment option. The company's pipeline includes additional candidates in various stages of development.